Advanced Parkinson’s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study
- 24 March 2025
- journal article
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 15 (2-3) , 65-76
Abstract
This study investigates the prevalence and clinical features of advanced Parkinson's disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG). We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and health-related quality of life data. Logistic regression identified factors predicting disease progression and DATs eligibility. This study included 370 patients with Parkinson's disease, of whom 44.6% (95%CI: 39.5%-49.8%) had APD. Each additional year of disease duration increased APD odds by 8% (ORa = 1.08, p = 0.047). Overall, 38.9% of patients qualified for at least one DAT, including 18.9% for DBS, 35.4% for CSAI, and 13.8% for LCIG; however, only one patient received DBS. Younger age at onset was associated with greater DATs eligibility, with each additional year reducing eligibility by 7% (ORa = 0.93, p < 0.001). Additionally, premotor REM sleep behavior disorder increased the odds of LCIG eligibility (ORa = 2.38, p = 0.009), while prior sports engagement nearly tripled the odds for CSAI (ORa = 2.87, p = 0.038). Although many Moroccan patients qualify for DATs, their use is minimal. Addressing access barriers is crucial to improve outcomes.Keywords
This publication has 39 references indexed in Scilit:
- Continuous Subcutaneous Foslevodopa‐Foscarbidopa in Parkinson's Disease: A Mini‐Review of Current Scope and Future OutlookMovement Disorders Clinical Practice, 2024
- Medical and surgical management of advanced Parkinson's diseaseMovement Disorders, 2018
- Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is neededJournal of Neural Transmission, 2017
- MDS clinical diagnostic criteria for Parkinson's diseaseMovement Disorders, 2015
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- The motor phenotype of Parkinson's disease in relation to age at onsetMovement Disorders, 2011
- Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's diseaseMovement Disorders, 2009
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008
- Motor fluctuations and dyskinesias in advanced/end stage Parkinson’s disease: a study from a population of brain donorsJournal of Neural Transmission, 2006
- Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)Movement Disorders, 1999